| scholarly article | Q13442814 |
| P50 | author | Jason K H Lee | Q84698486 |
| P2093 | author name string | Raymond Lai | |
| Robert J Ingham | |||
| Joel D Pearson | |||
| Julinor T C Bacani | |||
| P2860 | cites work | Anaplastic lymphoma kinase: signalling in development and disease | Q24312329 |
| Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis | Q24317141 | ||
| ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) | Q24336482 | ||
| Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation | Q24336817 | ||
| Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors | Q24595585 | ||
| Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5) | Q24595848 | ||
| Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene | Q24598210 | ||
| Identification of ALK as a major familial neuroblastoma predisposition gene | Q24655923 | ||
| TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors | Q24669567 | ||
| Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer | Q27851410 | ||
| Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma | Q27851421 | ||
| Activating mutations in ALK provide a therapeutic target in neuroblastoma | Q27851452 | ||
| Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers | Q27851486 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. | Q27851589 | ||
| Crizotinib in anaplastic large-cell lymphoma | Q27851624 | ||
| Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. | Q27851704 | ||
| Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B | Q27860731 | ||
| The phosphoinositide 3-kinase pathway | Q27860738 | ||
| TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations | Q28137713 | ||
| Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1 | Q28142184 | ||
| Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death | Q28202067 | ||
| Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin | Q28208159 | ||
| Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor | Q28214316 | ||
| Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types | Q28214927 | ||
| The dependence receptor hypothesis | Q28240263 | ||
| Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma | Q28250347 | ||
| Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3 | Q28253494 | ||
| Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks | Q28255399 | ||
| Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer | Q28276022 | ||
| Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum | Q28298351 | ||
| ALK rearrangement in sickle cell trait-associated renal medullary carcinoma | Q28302654 | ||
| Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system | Q28304840 | ||
| Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications | Q28506804 | ||
| Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer | Q29547564 | ||
| Stats: transcriptional control and biological impact | Q29547776 | ||
| Molecular mechanisms of mTOR-mediated translational control | Q29615529 | ||
| Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
| Major nucleolar proteins shuttle between nucleus and cytoplasm | Q29620425 | ||
| Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth | Q30156817 | ||
| Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K. | Q30160333 | ||
| Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma | Q33275224 | ||
| Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer | Q33386997 | ||
| KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer | Q33433329 | ||
| The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner | Q40230532 | ||
| Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma | Q40251046 | ||
| Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma | Q40258085 | ||
| Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma | Q40259870 | ||
| SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling | Q40318278 | ||
| Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells | Q40357248 | ||
| Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. | Q40371805 | ||
| JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma | Q40377891 | ||
| Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. | Q40424263 | ||
| NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. | Q40482603 | ||
| Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma | Q40514814 | ||
| ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth | Q40540326 | ||
| Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells | Q40543147 | ||
| Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL). | Q40582412 | ||
| Identification of NPM-ALK interacting proteins by tandem mass spectrometry. | Q40589160 | ||
| NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a | Q40590126 | ||
| Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma | Q40594788 | ||
| Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma | Q40761648 | ||
| Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis | Q40815965 | ||
| Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway | Q40838398 | ||
| Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis | Q40895235 | ||
| CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. | Q41199240 | ||
| Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies | Q41923524 | ||
| The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. | Q42024265 | ||
| NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells | Q42052786 | ||
| JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis | Q42278940 | ||
| Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas | Q42586803 | ||
| Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. | Q42639021 | ||
| A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma | Q42804740 | ||
| Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification | Q42812847 | ||
| A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma'). | Q42818441 | ||
| Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma | Q43580523 | ||
| A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis | Q43636796 | ||
| Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma | Q43665317 | ||
| Possible association between nonsynonymous polymorphisms of the anaplastic lymphoma kinase (ALK) gene and schizophrenia in a Japanese population. | Q43751749 | ||
| NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. | Q44211040 | ||
| A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene | Q44270446 | ||
| ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases | Q44451877 | ||
| Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma | Q44473991 | ||
| Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma | Q44559500 | ||
| Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. | Q44605512 | ||
| Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. | Q44605515 | ||
| Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma | Q45022834 | ||
| Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion | Q46405228 | ||
| Involvement of Cot activity in the proliferation of ALCL lymphoma cells. | Q46797208 | ||
| Characterization of the expression of the ALK receptor tyrosine kinase in mice | Q46927486 | ||
| Detection of the t(2;5)(p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma | Q47632161 | ||
| ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma | Q49029662 | ||
| Anaplastic lymphoma kinase and leukocyte tyrosine kinase: functions and genetic interactions in learning, memory and adult neurogenesis. | Q50601381 | ||
| Myoblast determination in the somatic and visceral mesoderm depends on Notch signalling as well as on milliways(mili(Alk)) as receptor for Jeb signalling. | Q52553075 | ||
| JunB inhibits proliferation and transformation in B-lymphoid cells. | Q53377179 | ||
| Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma. | Q53532373 | ||
| Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. | Q53605317 | ||
| ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC). | Q53920594 | ||
| Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA. | Q54631021 | ||
| The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. | Q54738505 | ||
| The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration | Q58065800 | ||
| High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours | Q61696748 | ||
| Identification and characterization of a hexameric form of nucleolar phosphoprotein B23 | Q69052348 | ||
| Cross-linkage of nucleophosmin in tumor cells by nitrogen mustard | Q69609498 | ||
| Expression and subcellular locations of two forms of nucleolar protein B23 in rat tissues and cells | Q72721383 | ||
| Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1 | Q73063969 | ||
| Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor | Q73182222 | ||
| Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma | Q73300154 | ||
| Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like) | Q73783320 | ||
| ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor | Q73855692 | ||
| A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation | Q77363627 | ||
| Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors | Q77926025 | ||
| PTEN and p27 expression in mature T-cell and NK-cell neoplasms | Q81286052 | ||
| Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma | Q38340761 | ||
| Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma | Q38350139 | ||
| NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis | Q39426055 | ||
| Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma | Q39430752 | ||
| Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer | Q39574492 | ||
| NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma | Q39590992 | ||
| Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. | Q39647760 | ||
| ALK-positive extramedullary plasmacytoma with expression of the CLTC-ALK fusion transcript | Q39715888 | ||
| C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway | Q39762430 | ||
| B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. | Q39809008 | ||
| Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation. | Q39869731 | ||
| Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. | Q39879636 | ||
| Oncogenic mutations of ALK kinase in neuroblastoma | Q39928776 | ||
| Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma | Q39928780 | ||
| STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression | Q40070793 | ||
| Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. | Q40160132 | ||
| The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms | Q40207635 | ||
| Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). | Q33606105 | ||
| ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions | Q33707493 | ||
| STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes | Q33784496 | ||
| An evolutionary conserved role for anaplastic lymphoma kinase in behavioral responses to ethanol | Q33974947 | ||
| Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4--anaplastic lymphoma kinase gene fusion | Q34086155 | ||
| Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms | Q34099059 | ||
| Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma | Q34136298 | ||
| KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only | Q34162787 | ||
| Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor | Q34450749 | ||
| Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. | Q34552993 | ||
| Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene | Q34593929 | ||
| Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3 | Q34773094 | ||
| IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK. | Q35123227 | ||
| Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. | Q35131224 | ||
| Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS | Q35220408 | ||
| Rheb fills a GAP between TSC and TOR. | Q35579532 | ||
| Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor | Q35747060 | ||
| ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). | Q35809839 | ||
| Expression of the ALK tyrosine kinase gene in neuroblastoma | Q35810214 | ||
| Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells | Q35849172 | ||
| Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. | Q35933411 | ||
| Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma | Q36193920 | ||
| Dynamic FoxO transcription factors | Q36889897 | ||
| The anaplastic lymphoma kinase in the pathogenesis of cancer | Q37039605 | ||
| Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). | Q37081609 | ||
| IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma | Q37278507 | ||
| Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? | Q37439553 | ||
| Many paths to one goal? The proteins that recognize methylated DNA in eukaryotes | Q37468796 | ||
| MAPK signaling pathways in the regulation of hematopoiesis | Q37508518 | ||
| The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases | Q37814123 | ||
| Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. | Q37833502 | ||
| Signal transducers and activators of transcription-from cytokine signalling to cancer biology | Q37859135 | ||
| Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 | ||
| Anaplastic lymphoma kinase in human cancer | Q37866541 | ||
| The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling | Q38299315 | ||
| Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target | Q38326252 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 123253 | |
| P577 | publication date | 2012-07-18 | |
| P1433 | published in | Journal of Signal Transduction | Q26841830 |
| P1476 | title | NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases | |
| P478 | volume | 2012 |
| Q54358602 | ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC. |
| Q48528844 | Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. |
| Q42697768 | Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR. |
| Q35863674 | Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease |
| Q95841197 | Diagnostic Capability of Next-Generation Sequencing Fusion Analysis in Identifying a Rare CASE of TRAF1-ALK-Associated Anaplastic Large Cell Lymphoma |
| Q38870250 | Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors |
| Q38962008 | Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs. |
| Q36082481 | Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity? |
| Q43184268 | Kinase overexpressing cancers responsive to drug withdrawal. |
| Q36602853 | MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies |
| Q38874456 | NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair |
| Q34489388 | PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases. |
| Q38956444 | Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions |
| Q35200337 | Role of HGF/MET axis in resistance of lung cancer to contemporary management |
| Q41133791 | TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. |
| Q38956321 | Targeted inhibition in tumors with ALK dependency |
| Q91718675 | The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma |
Search more.